Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Neovasc Inc (NVCN.TO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 48,161
  • Shares Outstanding, K 70,825
  • Annual Sales, $ 1,749 K
  • Annual Income, $ -108,043 K
  • 60-Month Beta 4.80
  • Price/Sales 15.68
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -7.46
  • Most Recent Earnings -0.21 on 03/31/19
  • Next Earnings Date 05/09/19
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate 0.00
  • Number of Estimates 1
  • High Estimate 0.00
  • Low Estimate 0.00
  • Prior Year 0.00
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.62 +9.68%
on 05/21/19
1.14 -40.35%
on 05/23/19
-0.04 (-5.56%)
since 04/24/19
3-Month
0.50 +36.00%
on 03/27/19
1.14 -40.35%
on 05/23/19
-0.16 (-19.05%)
since 02/22/19
52-Week
0.50 +36.00%
on 03/27/19
6.00 -88.67%
on 08/08/18
-5.32 (-88.67%)
since 05/24/18

Most Recent Stories

More News
Neovasc Announces Positive Two-Year Follow-up Safety and Efficacy Data for the Neovasc Reducer(TM) in a Peer Reviewed Article in the International Journal of Cardiology

NASDAQ, TSX: NVCN

NVCN : 0.51 (-4.15%)
NVCN.TO : 0.68 (-5.56%)
Neovasc Announces Closing of Private Placement of Convertible Debt and Common Shares for Gross Proceeds of US$11.5 Million

NASDAQ, TSX: NVCN

NVCN : 0.51 (-4.15%)
NVCN.TO : 0.68 (-5.56%)
Neovasc Announces Closing of Private Placement of Convertible Debt and Common Shares for Gross Proceeds of US$11.5 Million

NASDAQ, TSX: NVCN

NVCN : 0.51 (-4.15%)
NVCN.TO : 0.68 (-5.56%)
Neovasc Announces Private Placement of Convertible Debt and Equity for Gross Proceeds of US$11.5 Million

Upon closing of this agreement, cash and cash equivalents is expected to support operations into Q1 2020

NVCN : 0.51 (-4.15%)
NVCN.TO : 0.68 (-5.56%)
/C O R R E C T I O N from Source -- Neovasc Inc./

The news release, Neovasc Announces First Quarter 2019 Financial Results, published at 4:00 p.m. ET on May 9, 2019 inadvertently included a statement that the Company had announced a financing....

NVCN : 0.51 (-4.15%)
NVCN.TO : 0.68 (-5.56%)
Neovasc Announces Treatment of 1,000th Refractory Angina Patient with Neovasc Reducer™

NASDAQ, TSX: NVCN

NVCN : 0.51 (-4.15%)
NVCN.TO : 0.68 (-5.56%)
Neovasc Announces Treatment of 1,000th Refractory Angina Patient with Neovasc Reducer™

NASDAQ, TSX: NVCN

NVCN : 0.51 (-4.15%)
NVCN.TO : 0.68 (-5.56%)
Neovasc to Announce First Quarter 2019 Financial Results on Thursday, May 9th

Conference Call Scheduled for 4:30 pm Eastern Time on May 9 th  

NVCN : 0.51 (-4.15%)
NVCN.TO : 0.68 (-5.56%)
Neovasc Provides Highlights from Annual Conference of the DGK, the German Society of Cardiology; Symposium Generates Growing Support for Reducer

NASDAQ, TSX: NVCN

NVCN : 0.51 (-4.15%)
NVCN.TO : 0.68 (-5.56%)
Neovasc Announces Resolution of Last Remaining Active Litigation

NASDAQ, TSX: NVCN

EW : 169.38 (-0.35%)
NVCN : 0.51 (-4.15%)
NVCN.TO : 0.68 (-5.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More Share

Key Turning Points

2nd Resistance Point 0.75
1st Resistance Point 0.71
Last Price 0.68
1st Support Level 0.64
2nd Support Level 0.61

See More

52-Week High 6.00
Fibonacci 61.8% 3.90
Fibonacci 50% 3.25
Fibonacci 38.2% 2.60
Last Price 0.68
52-Week Low 0.50

See More

Business Summary

Neovasc Inc is a specialty medical device company. The company develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Tiara for the transcatheter treatment of mitral valve disease and the Neovasc Reducer for the treatment of refractory...

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar